

Monthly News – September 2012

Department of Psychiatry

September 24, 2012 Volume 6, Number 9

Into the Light Walk: Sunday, September 30th

According to The Ohio Department of Mental Health, approximately 20 percent of high school students have seriously considered suicide. Help increase suicide prevention programming by participating in the Into the Light Walk, a fundraiser presented by the Suicide Prevention Education Alliance (SPEA). The walk will be held at the Cleveland Metroparks Zoo on Sept. 30 from 6:00-8:30 p.m. Registration is \$20 per person. Participants who raise \$100 will receive a Lifesaver t-shirt at the walk.

Go to www.intothelightwalk.org click on *Join A Team*, and enter our team name 'University Hospitals Psychiatry Residents' to donate or register. Please contact Almeria Decker for any questions: (almeria.decker@uhhospitals.org).

General News:

September is Recovery Month and **Ray Isackila, Assistant Clinical Administrator of Addiction Recovery Services**, in partnership with UH Employee Assistance Program, will give a talk on Dual Diagnosis. Many patients with substance use disorders have a co-occurring mental health condition along with their addiction and

research shows that both need to be treated for a successful outcome. The presentation will be held on **Wednesday, September 26th**, in the Kulas Auditorium from noon to 1:00 PM. Bring your lunch and learn more about mental health and substance use disorders.

The Center for Evidence Based Practices at Case Western Reserve University in collaboration with Shawnee Mental Health Center, Inc., has developed The Integrated Treatment Tool: A Tool to Evaluate the Integration of Primary and Behavioral Health Care ©. This innovation was made possible as the result of a grant from the Substance Abuse and Mental Health Services Administration (SAMHSA). This new instrument is a 30-item planning and evaluation document which guides an organizational change process that facilitates the integration of primary and behavioral healthcare services.

Patrick E. Boyle, MSSA, LISW-S, LICDC, director of implementation services at the Center for Evidence-Based Practices, explains that the CEBP will use the new Integrated Treatment Tool to help organizations in Ohio and nationally begin the process of integrating primary healthcare into services for people with behavioral healthcare issues (e.g., serious mental illness

and co-occurring substance use disorders). Even if an organization is not able to embed primary care within its behavioral health facilities and services, the tool is still relevant and useful, because it helps organizations achieve important incremental goals, which, over time, add up. "This stage-wise approach is important," Boyle says. "It sets a realistic, manageable pace for achieving and sustaining change and improved outcomes over time. It identifies organizational components and clinical services that are most important for the organization to change and grow."

For more information or to download a brochure, go to: <http://www.centerforebp.case.edu/stories/implementation-tool-for-integrated-primary-and-behavioral-healthcare>

Congratulations:

Robert W. Goldberg, Ph.D., ABPP received the Distinguished Service Award of the VA Psychology Training Council for his service as Chair. The VAPTC is the national membership group for VA psychology training program directors. In addition, he received the Dedicated Service Award from the Geauga County Board of Mental Health and Recovery Services for his nine years on the Board, including the past 3 years as its Chairman.

Dr. Pythias Jones has been elected 2nd Vice Chairman of the Alcohol Drug Addiction and Mental Health Services Board of Cuyahoga County.

Congratulations to **Joanne Vincelli** and her husband Pascal on the celebration of their 35th wedding anniversary. Their daughter arranged a trip to Hawaii for them as a second honeymoon.

Grand Rounds:

September 28th:

Mayer-Haber Lecture *

Speaker: Jeffrey A. Lieberman, M.D.

Topic: Prevention of Schizophrenia through Early Intervention: Feasible or Fantasy?

October 5th:

5th Annual Rocco L. Motto Lecture *

Speaker: Lawrence D. Scahill, MSN, Ph.D.

Topic: Psychopharmacology in Autism: 15 years of Progress and a Long Way to Go

October 12th:

Speaker: Robert L. Findling, MD, MBA *

Topic: Evolution in Treatment Research in the Division of Child & Adolescent Psychiatry

October 19th:

2nd Annual

Miriam B. Rosenthal Lecture *

Speaker: Susan Hatters-Friedman, M.D.

Topic: Psychiatric Treatment In Pregnancy And Malpractice

October 26th:

Douglas Danford Bond Lecture*

Speaker: Jean A. King, Ph.D.

Topic: Nicotine Effects on the Brain: Much More than Reward

**** Reception immediately following the lecture in the Mayer-Haber Conference Room 13-113***

Presentations and Publications:

Christina Delos Reyes, M.D., was interviewed on WCPN Ideastream on Wednesday, September 19th on the subject of Teenage vulnerability to addiction. Ideastream has examined the many facets of addiction as part of their Be Well health series during the month of September.

Dr. Delos Reyes was also interviewed in the September 7th issue of *Psychiatric Times* for an article on the use of Motivational Interviewing in the treatment of addiction.

Susan Hatters-Friedman, MD, and Renee Sorrentino, MD. Postpartum Psychosis, Infanticide and Insanity: Implications for Forensic Psychiatry. Journal of the American Academy of Psychiatry and the Law. 40:326-332, 2012.

Susan Hatters-Friedman, MD. The Psychology of Female Violence: Crimes Against the Body. Book Review. Journal of the American Academy of Psychiatry and the Law, 40: 442-444, 2012

The Employee Assistance Program (EAP) sponsored a brown bag workshop on Wednesday August 29th from noon –1 p.m. in Kulas Auditorium titled, "Diagnosing and Treating Attention Deficit Hyperactivity Disorder (ADHD)." Keynote speaker, **John Hertzner, MD**, discussed the process for diagnosing ADHD, common ADHD treatment options and risks associated with leaving ADHD untreated.

Nocjar, C.; Zhang, J.; Feng, P.; Panksepp, J (2012). The social-defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of dynorphin and orexin in the hypothalamus. *Neuroscience*, 218: 138-153.

Pagano, M. E., White, W. L., Kelly, J. K., Stout, R. L., Johnson, S. M., Carter, R. R. & Tonigan, J. S. (in press). The 10 year course of aa participation and long-term outcomes: A Follow-up study of outpatient subjects in Project MATCH. *Journal of Substance Abuse*. doi: 0.1080/08897077.2012.691450 NIHMS385630

Dr. Phillip Resnick presented a Grand Rounds at Wright State University on September 18th on Malingered Psychosis and a lecture on Deposition Testimony in South Padre Island, Texas on September 22nd.

Scur, M.D. Letter to the Editor: Impact of AA-related helping on long-term outcomes. *Alcoholism and Drug Abuse Weekly*, 24 (33), p.5.

Addiction Psychiatry Fellow, **Kathleen Svala, M.D.**, will speak on *Women in Recovery*, Thursday, October 4th, from 5:00 to 6:00 p.m. at Addiction Recovery Services. The lecture will focus on the unique effect alcohol has on women as well as addressing important health issues for women as they recover.

Research:

The Discovery and Wellness Center for Children at University Hospitals is currently enrolling children ages 6-17 years for a research study. Subjects must have a primary diagnosis of bipolar disorder, schizophrenia spectrum disorder or any other psychiatric disorder requiring treatment with medication. If eligible, your child will receive a study-related evaluation, study medication and close follow up during the research study from a doctor who specializes in pediatric mental illness. To learn more about this research study, please call 216-844-3922.

Research Study

Study for older adults (≥ 60 years) with type I Bipolar Disorder who are currently sub-optimally

responsive to their prescribed BD treatments will receive 12 weeks of open-label Asenapine. Each study subject will serve as their own baseline control and mood symptoms will be assessed using standardized measures during the 12 weeks of Asenapine therapy. The primary outcome is change from baseline in bipolar mood symptom scores (mania and depression). Secondary outcomes include functional and general health status, global psychopathology, side effects, and extrapyramidal symptoms.

To participate, individuals must:

- 1.) Type I Bipolar disorder
- 2.) Age 60 or older
- 3.) Sub-optimal response to current psychotropic management including:
 - a. Behaviors and symptoms of irritability, agitation, mood lability or diminished ability to interact with others in their place of residence
 - b. Diminished ability to take care of basic personal needs in their place of residence due to symptoms of BD

To participate, individuals may NOT have:

- 1.) History of intolerance or resistance to asenapine
- 2.) Clinical diagnosis of dementia or Mini-mental state (MMSE) < 24
- 3.) History of TIA, stroke or MI within the past 12 months
- 4.) Medical illness that is the clear, underlying etiology of BD
- 5.) Unstable medical illness or condition including prolonged QT interval
- 6.) Substance dependence (except nicotine or caffeine) within the past 3 months.
- 7.) Rapid cycling BD defined as 4 or more discrete mood episodes within the previous 12 months.
- 8.) At high risk for self-harm or suicide

For more information or to refer a patient contact Edna Fuentes-Casiano at 216-844-2104 or Effectiveness.Research@UHHospitals.org

Double-Blind, Placebo-Controlled Trial of Pioglitazone for Insulin-Resistant Bipolar Depression

PURPOSE: Patients with bipolar disorder have higher rates of insulin resistance than the general population. Currently, physicians do not know whether treating insulin resistance in people with bipolar disorder will lead to a decrease in depressive symptoms. The purpose of this study is to test whether pioglitazone, a medication that improves the efficiency of how the body uses blood sugar, is able to reduce depression severity.

ELIGIBILITY: Participants must be over the age of 18 with Bipolar Disorder (I, II, NOS); currently receiving treatment with an anti-manic drug or willing to receive treatment with an anti-manic drug. The following are considered anti-manic drugs: lithium, divalproex, carbamazepine, lamotrigine, olanzapine, quetiapine, risperidone, aripiprazole, asenapine, or ziprasidone. Participants cannot have a history of bladder cancer or heart failure. Participants cannot be diagnosed with dementia or taking insulin or rosiglitazone.

PRINCIPAL INVESTIGATOR: David Kemp, MD

RESEARCH COORDINATOR: Carla Conroy, 216/844-2871, Carla.Conroy@UHHospitals.org

Save the Date:

The Connor Integrative Medicine Network will offer the “Heal the Healer” symposium on **Friday, October 12th** from 7:45-4:00 p.m. The event will take place at the Hawthorne Valley Golf Club. “Connect with your fellow caregivers at a day designed to stimulate your mind, treat your body and lift your spirit.” CME’s and CEU’s are available for this symposium. To register or for more information call: 216-488- 4757.

Center for Evidence-Based Practices, Conference 2012

Dates: **Oct 22 & 23, 2012**

Location: Cleveland Airport Marriott; Cleveland, OH.

CEUs: Up to 10.5 CEUs, also Supervision & Ethics credits. Cost for Ohio providers: \$200/ \$125

Cost for Non-Ohio providers: \$300/ \$225

Deadline to register is October 8th.

Learn More & Register Online:

<http://www.centerforebp.case.edu/events/conference-2012>

Contact:

Published by University Hospitals Dept. of Psychiatry
DEADLINE FOR NEXT

ISSUE: Friday, 10/12/2012

CONTACT: Kate Kilbane
Phone: 216-844-3658
kate.kilbane@uhhospitals.org